[1] 中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病分会重型肝病与人工肝学组. 肝衰竭诊疗指南[J]. 实用肝脏病杂志，2006，9：321-324.
[2] TSUBOTA A，ARASE Y，SAITOH S，et al. Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection:a preliminary study[J]. Am J Gastroenterol，2001，96（2）:557-562.
[3] TSUBOTA A，ARASE Y，SUZUKI Y，et al. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B[J]. J Gastroenterol Hepatol，2005，20（3）：426-432.
[4] SCHMILOVITZ W，BEN-ARI Z，SIKULER E，et al. Lamivudine treatment for acute severe hepatitis B:a pilot study[J]. Liver Int，2004，24:547-551.
[5] TILLMANN HL，HADEM J，LEIFELD L，et al. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B，amulticenter experience[J]. J Viral Hepat，2006，13（4）:256-256.
[6] MIYAKE Y，IWASAKI Y，TAKAKI A，et al. Lamivudine treatment improves the prognosis of fulminant hepatitis B[J]. Intern Med，2008，47（14）:1293-1299.
[7] DELI■ D，NESI■ Z，PROSTRAN M，et al. Treatment of subacute hepatitis B with lamivudine:a pilot study in Serbia[J]. Vojnosanit Pregl，2009，66（3）:199-202.
[8] WONG VW，WONG GL，TSANG SW，et al. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen（HBeAg）-positive chronic hepatitis B[J]. Antivir Ther，2008，13:571-579.
[9] TSANG SW，CHAN HL，LEUNG NW，et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection[J]. Aliment. Pharmacol Ther，2001，15:1737-1744.
[10] CHAN HL，TSANG SW，HUI Y，et al. The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice[J]. J Viral Hepat，2002，9（6）:424-428.
[11] KUMAR M，SATAPATHY S，MONGA R，et al. A randomized controlled trial of lamivudine to treat acute hepatitis B[J]. Hepatology，2007，45（1）:97-101.
[12] ANDREA L，FRANCESCO A，FEDERICA B，et al. Lamivudine treatment for severe acute HBV hepatitis[J]. Int J Med Sci，2008，5（6）:309-312.
[13] YURDAYDIN C，SOLLANO J，HADZIYANNIS S，et al. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine refractory，HBeAg+chronic hepatitis B patients. ETV2026[J]. J Hepatol，2006，44:S36.
[14] SIMSEK H，SCHIFFE E，GOODMAN Z，et al. Effects of entecavir and lamivudine on advanced liver fibrosis after 48 weeks of treatment in patients with CHB infection:Results of three pivotal trials[J]. J Hepatol，2006，44:S191.
[15] LAMPERTICO P. Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B[J]. J Hepatol，2006，45:457-460.
[16] 舒欣，许启桓，张卡，等. HBeAg阴性乙型肝炎ACLF患者的临床特征及抗病毒治疗短期疗效[J]. 中华实验和临床病毒学杂志，2008，22（6）:481-483.
[17] 舒欣，许启桓，张卡，等. 恩替卡韦在乙型肝炎慢加急性肝功能衰竭中的应用[J]. 中华传染病杂志，2009，27（5）：281-286.
[18] 肖光明，何凯茵，贾卫东，等. 恩替卡韦治疗慢性重型乙型肝炎的病例对照研究[J]. 中华实验和临床病毒学杂志， 2009，23（1）：56-58.
[19] CHEN J，HAN JH，LIU C，et al. Short-term entecavir therapy of chronic severe hepatitis B[J]. Hepatobiliary Pancreat Dis Int，2009，8:261-266.
[20] 杨清，龚作炯，胡丹凤. 阿德福韦酯治疗乙型肝炎肝硬化失代偿期患者96周的临床观察[J]. 中华肝脏病杂志， 2009，17（7）：515-519.
[21] 张嗣芳，莫文成，张礼宏，等. 膦甲酸钠治疗重型乙型肝炎32例疗效观察[J]. 中国医师杂志，2006，8（10）：1429-1430. |
